Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title><jats:p>The mechanisms of drug resistance development in the<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">Plasmodium falciparum</jats:named-content>parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of<jats:italic>Pfmspdbl2</jats:italic>for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (<jats:italic>P</jats:italic>= 0.04). The high frequency of<jats:italic>Pfmspdbl2</jats:italic>codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).</jats:p>

Original publication

DOI

10.1128/aac.03522-14

Type

Journal

Antimicrobial Agents and Chemotherapy

Publisher

American Society for Microbiology

Publication Date

03/2015

Volume

59

Pages

1770 - 1775